Death Receptors as Targets of Cancer Therapeutics

Current Cancer Drug Targets

Volumn 4, Issue 1, 2004, Pages 97-104

  Sheikh, M Saeed ^a   Huang, Ying ^a  

^a State University of New York Upstate Medical University: College of Medicine   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTINEOPLASTIC AGENT; CYCLOOXYGENASE 2 INHIBITOR; CYTOKINE RECEPTOR; DEATH RECEPTOR; DEATH RECEPTOR 3; DEATH RECEPTOR 4; DEATH RECEPTOR 5; DEATH RECEPTOR 6; ETANERCEPT; FAS ANTIGEN; FAS ASSOCIATED DEATH DOMAIN PROTEIN; FAS LIGAND; LIGAND; MONOCLONAL ANTIBODY; NONSTEROID ANTIINFLAMMATORY AGENT; PROTEIN TL1A; SULINDAC; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ANTIBODY; TUMOR NECROSIS FACTOR RECEPTOR 1; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; CANCER; CANCER CHEMOTHERAPY; CANCER THERAPY; CLINICAL TRIAL; DRUG EFFECT; DRUG EFFICACY; HUMAN; NONHUMAN; PROTEIN DOMAIN; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; RECEPTOR BINDING; REVIEW; RHEUMATOID ARTHRITIS; SIGNAL TRANSDUCTION;

ANIMALS; ANTIGENS, CD95; ANTINEOPLASTIC AGENTS; APOPTOSIS; APOPTOSIS REGULATORY PROTEINS; HUMANS; MEMBRANE GLYCOPROTEINS; NEOPLASMS; RECEPTORS, TNF-RELATED APOPTOSIS-INDUCING LIGAND; RECEPTORS, TUMOR NECROSIS FACTOR; TNF-RELATED APOPTOSIS-INDUCING LIGAND; TUMOR NECROSIS FACTOR-ALPHA;

EID: 1542409974     PISSN: 15680096     EISSN: None     Source Type: Journal    
DOI: 10.2174/1568009043481597     Document Type: Review

References (84)

1. Askkenazi, A.; Dixit, V. M. Apoptosis Control by Death and Decoy Receptors. Curr. Opin. Cell Biol. 1999, 11, 255-260.
2. Gross, A.; McDonnell, J. M.; Korsmeyer, S. J. BCL-2 Family Members and the Mitochondria In Apoptosis. Genes Dev. 1999, 13, 1899-1911.
3. Schulze-Osthoff, K.; Ferrari, D.; Los, M.; Wesselborg, S.; Peter, M. E. Apoptosis signaling by death receptors. Eur. J. Biochem. 1998, 254, 439-459.
4. Singh, A.; Ni, J.; Aggarwal, B. B. Death Domain Receptors and Their Role in Cell Demise. J. Interferon Cyto. Res. 1998, 18. 439-450.
5. Peter, M. E.; Krammer, P. H. The CD95(APO-1/Fas) DISC and Beyond. Cell Death Differ. 2003, 10, 26-35.
6. LeBlanc, H. N.; Ashkenazi, A. Apo2L/TRAIL and its Death and Decoy Cell Death Differ. 2003, 10, 66-75.
7. Itoh, N.; Nagata, S. A Novel Protein Domain Required for Apoptosis. J. Biol. Chem. 1993, 268, 10932-10937.
8. Tartaglia, L. A.; Ayres, T. M.; Wong, G. H. W.; Goeddel, D. V. A Novel Domain within the 55 kDa TNF Receptor Signals Cell Death. Cell 1993, 74, 845-853.
9. Jiang, Y.; Woronicz, J. D.; Liu, W.; Goeddel, D. V. Prevention of constitutive TNF receptor 1 signaling by silencer of death domain. Science 1999, 283, 543-546.
10. Sheikh, M. S.; Antinore, M. J.; Huang, Y.; Fornace, A. J. Jr. Ultraviolet-Irradiation-Induced Apoptosis is Mediated via Ligand Independent Activation of Tumor Necrosis Receptor 1. Oncogene 1998, 17, 2555-2563.
11. Rehemtulla, A.; Hamilton, C. A.; Chinnaiyan, A. M.; Dixit, V. M. Ultraviolet Radiation-Induced Apoptosis Is Mediated by Activation of CD-95 (Fas/APO-1). J. Biol. Chem. 1997, 272, 25783-257836.
12. Aragane, Y.; Kulms, D.; Metze, D.; Wilkes, G.; Poppelmann, B.; Luger, T.A.; Schwarz, T. Ultraviolet Light Induces Apoptosis via Direct Activation of CD95 (Fas/APO-1) Independently of Its Ligand CD95L. J. Cell Biol. 1998, 140, 171-182.
13. Golstein, P. FasL Binds Preassembled Fas. Science 2000, 288, 2328-2329.
14. Chan, F. K. M.; Chun, H. J.; Zheng, L.; Siegel, R. M.; Bui, K. L.; Lenardo, M. J. A Domain in TNF Receptors That Mediates Ligand-Independent Receptor Assembly and Signaling. Science 2000, 288, 2351-2354
15. Siegel, R. M.; Frederiksen, J. K.; Zacharisa, D. A.; Chan, F. K. M.; Johnson, M.; Lynch, D.; Tsien, R. Y.; Lenardo, M. J. Fas Preassociation Required for Apoptosis Signaling and Dominant Inhibition by Pathogenic Mutations. Science 2000, 288, 2354-2357.
16. Hsu, H.; Xiong, J.; Goeddel, D.V. The TNF Receptor 1-Associated Protein TRADD Signals Cell Death and NF-kappa B Activation. Cell 1995, 81, 495-504.
17. Chinnaiyan, A. M.; O'Rourke, K.; Tewari, M.; Dixit, V. M. FADD, a Novel Death Domain-Containing Protein, Interacts with Death Domains of Fas and Initiates Apoptosis. Cell 1995, 81, 505-572.
18. Boldin, M. P.; Goncharov, T. M.; Goltsev, Y. V.; Wallach, D. Involvement of MACH, a Novel MORT1/FADD-Interacting Protease, in Fas/APO-1- and TNF Receptor-Induced Cell Death. Cell 1996, 85, 803-815
19. Screaton, R. A.; Kiessling, S.; Sansom, O. J.; Millar, C. B.; Maddison, K.; Bird, A.; Clarke, A. R.; Frisch, S. M. Fas-Associated Death Domain Protein Interacts with Methyl-CpG Binding Domain Protein 4: A Potential Link between Genome Surveillance and Apoptosis. Proc. Natl. Acad. Sci. U.S.A. 2003, 100, 5211-5216.
20. Sheikh, M. S.; Huang, Y. The FADD is Going Nuclear. Cell Cycle 2003, 2, 346-347.
21. Wang, E.; Marcotte, R.; Petroulakis, E. Signaling Pathway for Apoptosis: A Racetrack for Life or Death. J. Cell. Biochem. 1999, 32/33, 95-102.
22. Kelliher, M. A.; Grimm, S.; Ishida, Y.; Kuo, F.; Stanger, B. Z.; Leder, P. The Death Domain Kinase RIP Mediates the TNF-Induced NF-κB Signal. Immunity 1998, 8, 297-303.
23. Wang, C-Y.; Mayo, M. W.; Korneluk, R. G.; Goeddel, D. V.; Baldwin, A. S. NF-κB Antiapoptosis: Induction of TRAF1 and TRAF2 and c-IAP1 and c-IAP2 to Suppress Caspase 8 Activation. Science 1999, 281, 1680-1683.
24. Aggarwal, B. B.; Kohr, W. J.; Hass, P. E.; Moffat, B.; Spencer, S. A.; Henzel, W. J.; Bringaman, T. S.; Nedwin, G. E.; Goeddel, D. V.; Harkins, R. N. Human Tumor Necrosis Factor. Production, Purification and Characterization. J. Biol. Chem. 1985, 260, 2345-2354.
25. Schall, T. J.; Lewis, M.; Koller, K. J.; Lee, A.; Rice, G. C.; Wong, G. H. W.; Gatanaga, T.; Granger, G. A.; Leutz, R.; Raab, H.; Kohr, W. J.; Goeddel, D. V. Molecular Cloning And Expression of a Receptor for Human Tumor Necrosis Factor. Cell 1990, 61, 361-370.
26. Wallach, D.; Varfolomeev, E.E.; Malinin, N.L.; Golstsev, Y.V.; Kovalenko, A.V.; Boldin, M. P. Tumor necrosis factor receptor and Fas signaling mechanisms. Annu. Rev. Immunol. 1999, 17, 331-367.
27. Rothe, J.; Lesslauer, W.; Lotscher, H.; Lang, Y.; Koebel, P.; Kontgen, F.; Althage, A.; Zinkernagel, R.; Steinmetz, M.; Bluethmann, H. Mice lacking the tumour necrosis factor receptor 1 are resistant to TNF-mediated toxicity but highly susceptible to infection by Listeria monocytogenes. Nature 1993, 364, 798-802.
28. Pfeffer, K.; Matsuyama, T.; Kundig, T.M.; Wakeham, A.; Kishihara, K.; Shahinian, A.; Wiegmann, K.; Ohashi, P.S.; Kronke, M.; Mak. T.W. Mice Deficient For The 55 kD Tumor Necrosis Factor Receptor Are Resistant to Endotoxic Shock, Yet Succumb to L. Monocytogenes Infection. Cell 1993, 73, 457-467.
29. Gardnerova, M.; Blanque, R.; Gardenr, C. R. The Use of TNF Family Ligands and receptors and agents which modify their interactions as therapeutic agents. Curr. Drug Targets 2000, 1, 327-364.
30. Elliott, M. J.; Maini, R. N.; Feldmann, M.; Long-Fox, A.; Charles, P.; Bijl, H.; Woody, J. N. Repeated Therapy with Monoclonal Antibody to Tumour Necrosis Factor Alpha (cA2) in Patients with Rheumatoid Arthritis. Lancet 1994, 344, 1125-1127.
31. Zelster, R.; Laticia, V.; Tanck, C.; Holyst, M. M.; Ritchlin, C.; Gaspari, A. A. Clinical, Histological, and Immunophenotypic Characteristics of Injection Site Reactions Associated with Etanercept a Recombinant Tumor Necrosis Factor a Receptor:Fc Fusion Protein. Arch. Dermatol. 2000, 137, 893-899.
32. Lie, B.L.; Tunemoto, D.; Hemmi, H.; Mizukami, Y.; Fukuda, H.; Kikuchi, H.; Kato, S.; Numao, N. Identification of the Binding Site of 55kDa Tumor Necrosis Factor Receptor by Synthetic Peptides. Biochem. Biophys. Res. Commun. 1992, 188, 503-509.
33. Doring, E.; Stigler, R.; Grutz, G.; von Baehr, R.; Schneider-Mergener, J. Identification and Characterization of a TNF Alpha Antagonist Derived from a Monoclonal Antibody. Mol. Immunol. 1994, 31, 1059-1067.
34. Takasaki, W.; Kajino, Y.; Kajino, K.; Murali, R.; Greene, M. I., Structure-Based Design and Characterization of Exocyclic Peptidomimetics That Inhibit TNF Alpha Binding To Its Receptor. Nat. Biotechnol. 1997, 15, 1266-1270.
35. Kumaratilake, L. M.; Rathjen, D. A.; Mack, P.; Widmer, F.; Prasertsiriroj, V.; Ferrante, A. A Synthetic Tumor Necrosis Factor-Alpha Agonist Peptide Enhances Human Polymorphonuclear Leukocyte-Mediated Killing of Plasmodium Falciparum in Vitro and Suppresses Plasmodium Chabaudi Infection in Mice. J. Clin. Invest. 1995, 95, 2315-2323.
36. Chang, H.Y.; Nishitoh, H.; Yang, X.; Ichijo, H.; Baltimore, D. Activation of Apoptosis Signal-Regulating Kinase 1 (Ask1) By the Adapter Protein Daxx. Science 1998, 281, 1860-1863.
37. Ponton, A.; Clement, M.V.; Stamenkovic, I. the Cd95 (Apo-1/Fas) Receptor Activates Nf-Kb Independently of Its Cytotoxic Function. J. Biol. Chem. Ib996, 217, 8991-8995.
38. O'connell, J.; Houston, A.; Bennett, M.W.; O'sullivan, G. C.; Shanahan, F. Immune Privilege Or Inflammation? Insights Into the Fas Ligand Enigma. Nature Med. 2001, 7. 271-274.
39. Nagata, S.; Golstein, P. the Fas Death Factor. Science 1995, 267, 1449-1456.
40. Sabelko-Downes, K. A.; Russell, J.H. the Role of Fas in Vivo As A Cause and Regulator of Pathogenesis. Curr. Opin. Immunol. 2000, 12, 330-335.
41. Daniel, P. T.; Wieder, T.; Strum, I.; Schulze-Osthoff, K. the Kiss of Death: Promises and Failures of Death Receptors and Ligands in Cancer Therapy. Leukemia 2001, 15, 1022-1032.
42. Mullauer, L.; Gruber, P.; Sebinger, D.; Buch, J.; Wohlfart, S.; Chott, A. Mutations in Apoptosis Genes: A Pathogenetic Factor For Human Disease. Mutation Res. 2001, 488, 211-231.
43. Lee, S.H.; Shin, M.S.; Park, W.S.; Kim, S.Y.; Dong, S.M.; Pi, J.H.; Lee, H.K.; Kim, H.S.; Jang, J.J.; Kim, C.S.; Kim, S.H.; Lee, J.Y.; Yoo, N.J. Alterations of Fas (Apo-1/Cd95) Gene in Transitional Cell Carcinomas of Urinary Bladder. Cancer Res. 1999, 59, 3068-3072.
44. Walker, P.R.; Saas, P.; Dietrich, P-Y. Tumor Expression of Fas Ligand (Cd951) and the Consequences. Curr. Opin. Immunol. 1998, 10, 564-572.
45. Shibakit, M.; Tachibana, M.; Dhar, D. K.; Kotoh, T.; Kinugasa, S.; Kubota, H.; Masunaga, R.; Nagasue, N. Prognostic Significance of Fas and Fas Ligand Expressions in Human Esophageal Cancer. Clin. Cancer Res. 1999, 5, 2464-2469.
46. Mottolese, M.; Buglioni, S.; Bracalenti, C.; Cardarelli, M.A.; Ciabocco, L.; Giannarelli, D.; Botti, C.; Natali, P.G.; Concetti, A.; Venanzi, F.M. Prognostic Relevance of Altered Fas (Cd95)-System in Human Breast Cancer. Int. J. Cancer 2000, 89, 127-132.
47. Ito, Y.; Monden, M.; Takeda, T.; Eguchi, H.; Umeshita, K.; Nagano, H.; Nakamori, S.; Dono, K.; Sakon, M.; Nakamura, M.; Tsujimoto, M.; Nakahara, M.; Nakao, K.; Yokosaki, Y.; Matsuura, N. the Status of Fas and Fas Ligand Expression Can Predict Recurrence of Hepatocellular Carcinoma. Br. J. Cancer 2000, 82, 1211-1217.
48. Kim, Y. S.; Kim, K. H.; Choi, J. A.; Lee, J. H.; Kim, H. K.; Won, N. H.; Kim, I. Fas (Apo-1/Cd95) Ligand and Fas Expression in Renal Cell Carcinomas: Correlation with the Prognostic Factors. Arch. Pathol. Lab. Med. 2000, 124, 687-93.
49. Ogasawara, J.; Watanabe-Fukunaga, R.; Adachi, M.; Matsuzawa, A.; Kasugai, T.; Kitamura, Y.; Itoh, N.; Suda, T.; Nagata, S. Lethal Effect of the Anti-Fas Antibody in Mice. Nature 1993, 364, 806-809.
50. Muller, M.; Wilder, S.; Bannasch, D.; Israeli, D.; Lehlbach, K.; Li-Weber, M.; Friedmann, S. L.; Galle, P. R.; Stremmel, W.; Oren, M.; Krammer, P. H. P53 Activates the Cd95 (Apo1/Fas) Gene in Response To DNA Damage by Anticancer Drugs. J. Exp. Med. 1998, 188, 2033-2045.
51. Owen-Schaub, L. B.; Zhang, W.; Cusack, J. C.; Angelo, L. S.; Santee, S. M.; Fujiwara, T.; Roth, J. A.; Deisseroth, A. B.; Zhang, W-W.; Kruzel, E.; Radinsky, R. Wild-Type P53 and A Temperature Sensitive Mutant Induce Fas/Apo-1 Expression. Mol. Cell. Biol. 1995, 15, 3032-3040.
52. Bennett, M.; Macdonald, K.; Chan, S.-W.; Luzio, J. P.; Simari, R.; Weissberg, P. Cell Surface Trafficking of Fas: a Rapid Mechanism of P53-Mediated Apoptosis. Science 1998, 274, 1363-1366.
53. Mo, Y-Y.; Beck, W. T. Dna Damage Signals Induction of Fas Ligand in Tumor Cells. Mol. Pharm. 1999, 55, 216-222.
54. Fuchs, E. J.; Mckenna, K.A.; Bedi, A. p53-Dependent Dna Damage-Induced Apoptosis Requires Fas/Apo-1-Independent Activation of Cpp32. Cancer Res. 1997, 57, 2550-2554.
55. Ruiz-Ruiz, M.C.; Lopez-Rivas, A. P53-Mediated Up-Regulation of Cd95 Is Not Involved in Genotoxic Drug-Induced Apoptosis of Human Breast Tumor Cells. Cell Death & Diff. 1999, 6, 271-280.
56. Bajorath, J. Analysis of Fas-Ligand Interactions Using a Molecular Model of the Receptor-Ligand Interface. J. Computer-Aided Mol. Desg. 1999, 13, 409-418.
57. Schneider, P.; Bodmer, J. L.; Holler, N.; Mattmann, C.; Scuderi, P.; Terskikh, A.; Peitsch, M.C.; Tschopp, J. Characterization of Fas (Apo-1, Cd95)-Fas Ligand Interaction. J. Biol. Chem. 1997, 272, 18827-18833.
58. Jeremias, I.; Debatin, K.M. Trail Induces Apoptosis and Activation of Nf-Kappa B. Eur. Cytokine Netw. 1998, 9, 687-688.
59. Hu, W. H.; Johnson, H.; Shu, H. B. Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand Receptors Signal Nf-Kappa B and Jnk Activation and Apoptosis Through Distinct Pathways. J. Biol. Chem. 1999, 274, 30603-30610.
60. Pan, G.; Ni, J.; Wei, Y.-F.; Yu, G-L.; Gentz, R.; Dixit, V. M. An Antagonist Decoy Receptor and a Death Domain-Containing Receptor for Trail. Science 1997, 277, 815-818.
61. Degli-Esposti, M.A.; Smolak, P.J.; Walczak, H.; Waugh, J.Y.; Huang, C-P. ; Dubose, R.F.; Goodwin, R.G.; Smith, C.A. Cloning and Characterization of Trail-R3, a Novel Member of the Emerging Trail Receptor Family. J. Exp. Med. 1997, 186, 1165-1170.
62. Sheridan, J.P.; Marsters, S.A.; Pitti, R.M.; Gurney, A.; Skubatch, M.; Baldwin, D.; Ramakrishnan, L.; Gray, C.L.; Baker, K.; Wood, W.I.; Goddard, A.D. ; Godowski, P.; Ashkenazi, A. Control of Trail-Induced Apoptosis by a Family of Signaling and Decoy Receptrors. Science 1997, 277, 818-821.
63. Pan, G.; O'rourke, K.; Chinnaiyan, A.M.; Ebner, R.; Ni, J.; Y-F.; Dixit, V.M. Trundd, a New Member of the Trail Receptor Family That Antagonizes Trail Signaling. Febs Lett. 1998, 424, 41-45.
64. Degli-Esposti, M.A.; Dougall, W.C.; Smolak, P.J.; Waugh, J.Y.; Smith, C.A.; Goodwin, R.G. The Novel Receptor Trail-R4 Induces Nf-κB and Protects Against Trail-Mediated Apoptosis, Yet Retains An Incomplete Death Domain. Immunity 1997, 7, 813-820.
65. Marsters, S.A.; Sheridan, J. P.; Pitti, R. M.; Huang, A.; Skubatach, M.; Baldwin, D.; Yuan, J.; Gurney, A.; Goddard, A.D.; Godowski, P.; Ashkenazi, A. A Novel Receptor for Apo21/Trail Contains a Truncated Death Domain. Curr. Biol. 1997, 7, 1003-1006.
66. Simonet, W. S.; Lacey, D. L.; Dunstan, C. R.; Kelley, M.; Chang, M. S.; Luthy, R.; Nguyen, H.Q.; Wooden, S.; Bennett, L.; Boone, T.; Shimamoto, G.; Derose, M.; Elliott, R.; Colombero, A.; Tan, H.L.; Trail, G.; Sullivan, J.; Davy, E.; Bucay, N.; Renshaw-Gegg, L.; Hughes, T.M.; Hill, D.; Pattison, W.; Campbell, P.; Boyle, W.J. Osteoprotegerin:A Novel Secreted Protein Involved in the Regulation of Bone Density. Cell 1997, 89, 309-319.
67. Griffith, T. S.; Chin, W. A.; Jackson, G. C.; Lynch, D. H.; Kubin, M. Z. Intracellular Regulation of Trail-Induced Apoptosis in Human Melanoma Cells. J. Immunol. 1998, 161, 2833-2840.
68. Ashkenazi, A.; Pai, R.C.; Fong, S.; Leung, S.; Lawrence, D. A.; Marsters, S. A.; Blackie, C.; Chang, L.; Mcmurtrey, A.E.; Hebert, A.; Deforge, L.; Koumenis, I.L.; Lewis, D.; Harris, L.; Bussiere, J.; Koeppen, H.; Shahrokh, Z.; Schwall, R.H. Safety and Antitumor Activity of Recombinant Soluble Apo2 Ligand. J. Clin. Invest. 1999, 104, 155-162.
69. Walczak, H.; Miller, R. E.; Ariail, K.; Gliniak, B.; Griffith, T.S.; Kubin, M.; Chin, W.; Jones, J.; Woodward, A.; Le, T.; Smith, C.; Smolak, P.; Goodwin, R.G.; Rauch, C. T.; Schuh, J. C.; Lynch, D. H. Tumoricidal Activity of Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand in Vivo. Nat. Med. 1999, 5, 157-163.
70. Jo, M.; Kim, T. H.; Seol, D. W.; Esplen, J. E.; Dorko, K.; Billiar, T. R.; Strom, S. C. Apoptosis Induced in Normal Human Hepatocytes by Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand. Nat. Med. 2000, 6, 564-567.
71. Wu, G.S.; Burns, T.F.; Mcdonald Iii, E.R.; Jiang, W.; Meng, R.; Krantz, I.D.; Kao, G.; Gan, D.D.; Zhou, J-Y.; Muschel, R.; Hamilton, S.R.; Spinner, N.B.; Markowitz, S.; Wu, G.; El-Deiry, W.S. Killer/Dr5 Is Dna Damage-Inducible P53-Regulated Death Receptor Gene. Nature Genet. 1997, 17, 141-143.
72. Sheikh, M. S.; Burns, T. F.; Huang, Y.; Wu, G. S.; Amundson, S.; Brooks, K. S.; Fornace, A. J. Jr.; El-Deiry, W. S. p53-Dependent and Independent Regulation of the Death Receptor Killer/Dr5 Gene Expression in Response to Genotoxic Stress and Tnfα. Cancer Res. 1998, 58, 1593-1598.
73. Nimmanapalli, R.; Perkins, C.L.; Orlando, M.; O'bryan, E.; Nguyen, D.; Bhalla, K.N. Pretreatment with Paclitaxel Enhances Apo-2 Ligand/Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand-Induced Apoptosis of Prostate Cancer Cells by Inducing Death Receptors 4 and 5 Protein Levels. Cancer Res. 2001, 61, 759-763.
74. Nesterov, A.; Lu, X.; Johnson, M.; Miller, G.J.; Ivashchenko, Y.; Kraft, A.S. Elevated Akt Activity Protects the Prostate Cancer Cell Line LNCap From Trail-Induced Apoptosis. J. Biol. Chem. 2001, 276, 10767-10774.
75. Burns, T. F.; El-Deiry W. S. Identification of Inhibitors of Trail-Induced Death (Itids) in the Trail-Sensitive Colon Carcinoma Cell Line Sw480 Using a Genetic Approach. J. Biol. Chem. 2001, 276, 37879-37886.
76. He, Q.; Luo, X.; Huang, Y.; Sheikh, M. S. Apo21/Trail Differentially Modulates the Apoptotic Effects of Sulindac and a Cox-2 Selective Non-Steroidal Anti-Inflammatory Agent in Bax-Deficient Cells. Oncogene 2002, 21, 6032-6040.
77. Tschopp, J.; Irmler, M.; Thome, M. Inhibition of Fas Death Signals by Flips. Curr. Opin. Immunol. 1998, 10, 552-558.
78. Zhang, X. D.; Franco, A.; Myers, K.; Gray, C.; Nguyen, T.; Hersey, P. Relation of TNF-Related Apoptosis-Inducing Ligand (Trail) Receptor and Flice-Inhibitory Protein Expression to Trail-Induced Apoptosis of Melanoma. Cancer Res. 1999, 59, 2747-2753.
79. Kim, K.; Fisher, M. J.; Xu, S.Q.; El-Deiry, W. S. Molecular Determinants of Response to Trail in Killing of Normal and Cancer Cells. Clin. Cancer Res. 2000, 6, 335-346.
80. Datta, S.R.; Brunet, A.; Greenberg, M.E. Cellular Survival: a Play in Three Akts. Genes Dev. 1999, 13, 2905-2927.
81. Griffith, T. S.; Wiley, S. R.; Kubin, M. Z.; Sedger, L. M.; Maliszewski, C. R.; Fanger, N. A. Monocyte-Mediated Tumoricidal Activity Via the Tumor Necrosis Factor-Related Cytokine, Trail. J. Exp. Med. 1999, 189, 1343-1354.
82. Fanger, N. A.; Maliszewski, C. R.; Schooley, K.; Griffith, T. S. Human Dendritic Cells Mediate Cellular Apoptosis via Tumor Necrosis Factor-Related Apoptosis-Inducing Ligand (TRAIL). J. Exp. Med. 1999, 190, 1155-1164.
83. Yin, M. J.; Yamamoto, Y.; Gaynor, R. B. the Anti-Inflammatory Agents Aspirin and Salicylate Inhibit the Activity of I(Kappa)B Kinase-Beta. Nature 1998, 396, 77-80.
84. Huang, Y.; He, Q.; Hillman, M. J.; Rong, R.; Sheikh, M. S. Sulindac Sulfide-Induced Apoptosis Involves Death Receptor 5 and the Caspase 8-Dependent Pathway in Human Colon and Prostate Cancer Cells. Cancer Res. 2001, 61, 6918-6924.